Friday’s Renewable Energy Wind and Solar Stocks Trading; (NASDAQ:BWEN), (OTC: CWET), (NYSE:MY), (NYSE:TSL)
Renewables are the world’s fastest-growing energy source
Point Roberts WA- Aug. 16, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for renewable energy stocks trading for Friday September 23, 2011.
According to a recent report from International Energy Outlook 2011 (IEO2011) released September 19th by the U.S. Energy Information Administration (EIA), Renewables are the world’s fastest-growing energy source, at 2.8% per year; renewables share of world energy growing to roughly 15% in 2035 .
Wind and Solar Stocks Trading
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading up $0.3999, up 0.06 (17.65%) 1:53PM EDT
Canadian Solar Inc. (NASDAQ:CSIQ) trading up $4.75, up 0.34 (7.71%) 1:57PM EDT
China Ming Yang Wind Power Group (NYSE: MY ) trading at $2.78, up 0.24 (9.45%)
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at$0.12
First Solar, Inc. (NasdaqGS: FSLR ) trading at $69.45, up 2.60 (3.89%) 1:59PM EDT
General Electric (NYSE: GE ) trading at $15.24, up 0.20 (1.33%) 2:00PM EDT
JA Solar Holdings. (NasdaqGS: JASO ) trading up at $2.20, up 0.10 (4.76%) 2:00PM EDT
JUHL WIND INC (OTC BB: JUHL ) trading at $0.91
Trina Solar (NYSE: TSL ) trading up at $7.78, up 0.34 (4.57%) 1:55PM EDT
Research Renewable energy stocks at Investorideas.com – 1300 stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Investor Snapshot - Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc, is designing and preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. www.cleanwindenergytower.com
E-mail: Info@cwetower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind and solar stocks
http://www.investorideas.com/Resources/Newsletter.asp
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com contact:
800.665.0411
Friday, September 23, 2011
Pharma and Biotech Stocks Reporting on Breast Cancer Treatments; (OTC: AEMD), (NASDAQ: SPPI), (NASDAQ:RXII), (OTCBB: GNBT)
Point Roberts, WA - September 23, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an update and recent news from Biotech, Pharma and Medical Technology stocks reporting on developments in the treatment of breast cancer.
Aethlon Medical (OTCBB: AEMD ), a pioneer in developing therapeutic filtration devices, announced this week, HER2osome™, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25% of new breast cancer diagnosis.
The goal of HER2osome™ therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer. Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.
Spectrum Pharmaceuticals, Inc.(NasdaqGS: SPPI ) announced Monday announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.
The primary objective of this Phase 1 study was to assess the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy. Secondary objectives of the study include assessing the pharmacokinetic and pharmacodynamic profiles of SPI-1620 and identifying the optimum dose of SPI-1620 to be used in future Phase 2 studies.
A total of 30 patients were enrolled in this study. Patients ranged in age from 41 to 77 years (median 61), and had prostate cancer (9/30), breast cancer (3/30), female reproductive malignancies (4/30), gastrointestinal cancer (3/30), and pancreatic cancer (2/30), among other types.
Roxy Pharmaceuticals Corporation (Nasdaq:RXII ) reported in a press release on Wednesday announced today that it licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas.
It also said it is pursuing development of a cancer vaccine for breast cancer. NeuVax consists of the E75 peptide derived from HER2 combined with the immune adjuvant granulocyte macrophage-colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the FDA granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) Treatment) study. The Phase 3 trial is expected to commence in the first half of 2012.
Generex Biotechnology Corporation's (OTCBB:GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that its lead drug candidate AE37, a novel HER-2/neu-targeted vaccine currently in Phase II development for the treatment of breast cancer, is featured in the October 2011 issue of Scientific American, in a story titled "A New Ally Against Cancer" by Eric von Hofe, Ph.D., President of Antigen Express.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source: www.Investorideas.com
Point Roberts, WA - September 23, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an update and recent news from Biotech, Pharma and Medical Technology stocks reporting on developments in the treatment of breast cancer.
Aethlon Medical (OTCBB: AEMD ), a pioneer in developing therapeutic filtration devices, announced this week, HER2osome™, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25% of new breast cancer diagnosis.
The goal of HER2osome™ therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer. Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.
Spectrum Pharmaceuticals, Inc.(NasdaqGS: SPPI ) announced Monday announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.
The primary objective of this Phase 1 study was to assess the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy. Secondary objectives of the study include assessing the pharmacokinetic and pharmacodynamic profiles of SPI-1620 and identifying the optimum dose of SPI-1620 to be used in future Phase 2 studies.
A total of 30 patients were enrolled in this study. Patients ranged in age from 41 to 77 years (median 61), and had prostate cancer (9/30), breast cancer (3/30), female reproductive malignancies (4/30), gastrointestinal cancer (3/30), and pancreatic cancer (2/30), among other types.
Roxy Pharmaceuticals Corporation (Nasdaq:RXII ) reported in a press release on Wednesday announced today that it licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas.
It also said it is pursuing development of a cancer vaccine for breast cancer. NeuVax consists of the E75 peptide derived from HER2 combined with the immune adjuvant granulocyte macrophage-colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the FDA granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) Treatment) study. The Phase 3 trial is expected to commence in the first half of 2012.
Generex Biotechnology Corporation's (OTCBB:GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that its lead drug candidate AE37, a novel HER-2/neu-targeted vaccine currently in Phase II development for the treatment of breast cancer, is featured in the October 2011 issue of Scientific American, in a story titled "A New Ally Against Cancer" by Eric von Hofe, Ph.D., President of Antigen Express.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source: www.Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Friday’s Electric Car Stocks Trading ; (OTC: EVCA) (TSLA), (NRG), (GE)
GE (NYSE:GE) showcases its portfolio of electric vehicles
Point Roberts WA- September 23, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for renewable energy stocks in the electric car and battery sector for Friday September 23. The sector continues to get a boost as GE (NYSE:GE) showcases its portfolio of electric vehicles.
GE Capital Fleet Services announced yesterday it broke ground on a customer experience and learning center that will showcase GE's comprehensive portfolio of electric vehicle deployment solutions and help GE commercial customers evaluate Eves and other alternative fuel vehicles for their fleets.
The center is being built on GE's campus in Eden Prairie, Minn., and is scheduled to open in spring 2012. GE is building the facility so its customers can experience electric cars and trucks from a variety of manufacturers first-hand and analyze vehicle performance, driver experiences, service requirements and operational efficiencies with GE fleet experts. The center will also eventually feature alternative fuel vehicles powered by other energy sources.
"At GE, we are committed to helping our customers incorporate electric vehicles and other alternative fuel technologies into their fleets," said Clarence Nunn, president and CEO of GE Capital Fleet Services. "We're looking forward to working closely with customers at our new center and sharing insights to help them improve environmental performance and reduce carbon emissions."
EV Sector Trading Snapshot
A123 Systems, Inc. (NasdaqGM: AONE) trading at $26.24 0.61, up (2.38%) 10:40AM EDT
ENER1, Inc. (NASDAQ: HEV) trading at $0.2245 0.0345 (18.16%) 10:57AM EDT
Ecotality, Inc. (NasdaqCM: ECTY) trading at $1.931, up 0.0513 (2.73%)
EVCARCO (OTCBB: EVCA)) trading at $.0003
GE (NYSE:GE) trading at $15.16. Up 0.12 (0.80%) 11:02AM EDT
NRG Energy, Inc. (NYSE: NRG ) at $22.20, up 0.50 (2.30%)
Tesla Motors, Inc. (NASDAQ: TSLA) trading up at $26.08, up 0.45 (1.76%) 11:03AM EDT
UQM Technologies, Inc. (NYSE Amex: UQM) trading up at $2.01, up 0.03 (1.52%)
Electric Car/ Green Car Company Investor Profile -
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Trade EV and Green Stocks:
Research over 1300 global publicly traded green stocks with the renewable energy stocks directory at Investorideas.com
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:800 665 0411
Source: www.Investorideas.com
GE (NYSE:GE) showcases its portfolio of electric vehicles
Point Roberts WA- September 23, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for renewable energy stocks in the electric car and battery sector for Friday September 23. The sector continues to get a boost as GE (NYSE:GE) showcases its portfolio of electric vehicles.
GE Capital Fleet Services announced yesterday it broke ground on a customer experience and learning center that will showcase GE's comprehensive portfolio of electric vehicle deployment solutions and help GE commercial customers evaluate Eves and other alternative fuel vehicles for their fleets.
The center is being built on GE's campus in Eden Prairie, Minn., and is scheduled to open in spring 2012. GE is building the facility so its customers can experience electric cars and trucks from a variety of manufacturers first-hand and analyze vehicle performance, driver experiences, service requirements and operational efficiencies with GE fleet experts. The center will also eventually feature alternative fuel vehicles powered by other energy sources.
"At GE, we are committed to helping our customers incorporate electric vehicles and other alternative fuel technologies into their fleets," said Clarence Nunn, president and CEO of GE Capital Fleet Services. "We're looking forward to working closely with customers at our new center and sharing insights to help them improve environmental performance and reduce carbon emissions."
EV Sector Trading Snapshot
A123 Systems, Inc. (NasdaqGM: AONE) trading at $26.24 0.61, up (2.38%) 10:40AM EDT
ENER1, Inc. (NASDAQ: HEV) trading at $0.2245 0.0345 (18.16%) 10:57AM EDT
Ecotality, Inc. (NasdaqCM: ECTY) trading at $1.931, up 0.0513 (2.73%)
EVCARCO (OTCBB: EVCA)) trading at $.0003
GE (NYSE:GE) trading at $15.16. Up 0.12 (0.80%) 11:02AM EDT
NRG Energy, Inc. (NYSE: NRG ) at $22.20, up 0.50 (2.30%)
Tesla Motors, Inc. (NASDAQ: TSLA) trading up at $26.08, up 0.45 (1.76%) 11:03AM EDT
UQM Technologies, Inc. (NYSE Amex: UQM) trading up at $2.01, up 0.03 (1.52%)
Electric Car/ Green Car Company Investor Profile -
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Trade EV and Green Stocks:
Research over 1300 global publicly traded green stocks with the renewable energy stocks directory at Investorideas.com
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:800 665 0411
Source: www.Investorideas.com
Thursday's NASDAQ Top Gainers: WWON, DEER, IRIS, SCMR
POINT ROBERTS, September 23, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday September 22nd. Nasdaq closed lower by 82.52 (-3.25%) to 2,455.67.
In spite of another significant down day in trading there were some notable winners on the NASDAQ.
Westwood One, (NASDAQ:WWON) was the top percentage gainer for the session closing higher by 0.57 (20.80%) to $3.31 after hitting a new 52-week low of $2.65 earlier in the session. The stock moved off from day’s high of $3.84. The stock is still down about 65% so far this year.
Westwood One (NASDAQ:WWON - News) is one of the nation's largest providers of network radio programming in the U.S. The Company announced earlier this month, a proposed merger of a subsidiary of Westwood One, Inc., with Verge Media Companies, Inc.
Deer Consumer Products (NASDAQ:DEER) gained 0.87 (18.79%) to close at $5.50 on no major news. The stock has soared 26% in the past week following news it anticipates reporting strong 3rd quarter product sales as it continues to conduct its normal course of business.
The stock has a 52-week range of $3.84-$13.00.
IRIS International (NASDAQ:IRIS) closed with an impressive gain of 1.18 (14.55%) to end the day at $9.29 after falling about 15% earlier in the session. The stock is still down over 9% so far this year.
Sycamore Networks,(NASDAQ:SCMR) ended at $17.89, up 2.00 (12.59%) on no news after hitting a new 52-week low of $15.60 earlier in the session. So far this year, the stock has lost 3% of its value.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
POINT ROBERTS, September 23, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday September 22nd. Nasdaq closed lower by 82.52 (-3.25%) to 2,455.67.
In spite of another significant down day in trading there were some notable winners on the NASDAQ.
Westwood One, (NASDAQ:WWON) was the top percentage gainer for the session closing higher by 0.57 (20.80%) to $3.31 after hitting a new 52-week low of $2.65 earlier in the session. The stock moved off from day’s high of $3.84. The stock is still down about 65% so far this year.
Westwood One (NASDAQ:WWON - News) is one of the nation's largest providers of network radio programming in the U.S. The Company announced earlier this month, a proposed merger of a subsidiary of Westwood One, Inc., with Verge Media Companies, Inc.
Deer Consumer Products (NASDAQ:DEER) gained 0.87 (18.79%) to close at $5.50 on no major news. The stock has soared 26% in the past week following news it anticipates reporting strong 3rd quarter product sales as it continues to conduct its normal course of business.
The stock has a 52-week range of $3.84-$13.00.
IRIS International (NASDAQ:IRIS) closed with an impressive gain of 1.18 (14.55%) to end the day at $9.29 after falling about 15% earlier in the session. The stock is still down over 9% so far this year.
Sycamore Networks,(NASDAQ:SCMR) ended at $17.89, up 2.00 (12.59%) on no news after hitting a new 52-week low of $15.60 earlier in the session. So far this year, the stock has lost 3% of its value.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Thursday, September 22, 2011
Wednesday's NASDAQ
Winners: OREX, FLML, MATR, JASO
POINT ROBERTS - September 22, 2011 - www.InvestorIdeas.com, a globalinvestor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday September 21st. NASDAQ closed lower by -52.05 (-2.01%) to 2538.19.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) was the top percentage gainer for the session closing higher by 0.72 (48.98%) to $2.19 after the company said that it is renewing development of the experiment obesity drug Contrave after reaching an agreement with U.S. regulators to further study heart risks.
Flamel Technologies (NASDAQ:FLML) surged 0.82 (18.34%) to close at $5.29 on major news. The stock has soared 33% over the past one week. It has a 52-week range of $4.50-$5.43.
Mattersight (NASDAQ:MATR) closed with an impressive gain of 0.62 (14.00%) to end the day at $5.05 extending its previous session rally of 4.50%. The stock is still down over 77% so far this year.
JA Solar Holdings (NASDAQ:JASO) ended at $2.25, up 0.25 (12.50%) on no news. The stock rallied following a 32% fall in the previous one week. The stock made a new 52-week low of $2.00 on Tuesday. So far this year, the stock has lost two third of its market capitalization.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energystocks , biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
POINT ROBERTS - September 22, 2011 - www.InvestorIdeas.com, a global
Orexigen Therapeutics, Inc. (NASDAQ:OREX) was the top percentage gainer for the session closing higher by 0.72 (48.98%) to $2.19 after the company said that it is renewing development of the experiment obesity drug Contrave after reaching an agreement with U.S. regulators to further study heart risks.
Flamel Technologies (NASDAQ:FLML) surged 0.82 (18.34%) to close at $5.29 on major news. The stock has soared 33% over the past one week. It has a 52-week range of $4.50-$5.43.
Mattersight (NASDAQ:MATR) closed with an impressive gain of 0.62 (14.00%) to end the day at $5.05 extending its previous session rally of 4.50%. The stock is still down over 77% so far this year.
JA Solar Holdings (NASDAQ:JASO) ended at $2.25, up 0.25 (12.50%) on no news. The stock rallied following a 32% fall in the previous one week. The stock made a new 52-week low of $2.00 on Tuesday. So far this year, the stock has lost two third of its market capitalization.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Consumer Electronic Stock Nyxio (OTC: NYXO) on the Run: Stock Continues Yesterday's Gains in Early Trading
POINT ROBERTS - September 22, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Consumer Electronic Company Nyxio Technologies Corporation (OTC: NYXO). The stock traded up in yesterday's trading session on news and is continuing with strong moves this morning in the first hour of trading. The stock is trading at $0.93, up 0.1080 (13.14%), trading as high as $0.095.
The stock first gained investor attention as a competitor in the fast growing Smart TV/Connected market, predicted to have explosive growth over the next few years,
The Company announced yesterday its latest product line on the market-the OMEGA tablets. The fully functioning, sleek and compact Windows 7 operating system tablet PCs are compatible with all forms of media, gaming and social networking.
"The new Nyxio OMEGA PCs are compact, stylish and professional," said Giorgio Johnson, founder and CEO of Nyxio. "Their versatility makes them the optimal choice for a multitude of users and the tablet's progressive features make them stand out from other brands on the market."
All three tablets in the OMEGA line-the Classic, Premier and Ultimate-feature Windows 7. The OMEGA Ultimate tablet also features a dual Win 7 and Android OS, and all tablets feature BlueStacks, which makes android apps compatible with the tablets. Integrated components also include Wi-Fi, Bluetooth, webcam and 3G. The touch-screen navigation enables users to move through applications and features easily. The optional keyboard case creates added protection and seamless transition when working, traveling or commuting. Currently, the OMEGA tablet line is available online at www.nyxio.com and pricing begins at $699.
Learn more about Smart TV's - Showcase Smart TV Stock
Emerging player - Nyxio Technologies Corporation (OTC: NYXO)
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/NYXO/
Request news or alerts on Nyxio Technologies Corporation (OTCBB: NYXO)
http://www.investorideas.com/Resources/Newsletter.asp
Nyxio Technologies (OTC: NYXO) was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as with the world's first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company with more than 15 knowledgeable employees. For more information visit: www.nyxio.com.
INVESTOR RELATIONS
Summit IR Services, Inc.
Phone: 1-855-436-6996 (NYXO)
info@nyxiotech.com
www.nyxio.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. NYXO is a paid advertising showcase company on Investorideas.com - three thousand per month from a third party
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
http://www.investorideas.com/About/Contact.asp
800-665-0411
Source - Investorideas.com
POINT ROBERTS - September 22, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Consumer Electronic Company Nyxio Technologies Corporation (OTC: NYXO). The stock traded up in yesterday's trading session on news and is continuing with strong moves this morning in the first hour of trading. The stock is trading at $0.93, up 0.1080 (13.14%), trading as high as $0.095.
The stock first gained investor attention as a competitor in the fast growing Smart TV/Connected market, predicted to have explosive growth over the next few years,
The Company announced yesterday its latest product line on the market-the OMEGA tablets. The fully functioning, sleek and compact Windows 7 operating system tablet PCs are compatible with all forms of media, gaming and social networking.
"The new Nyxio OMEGA PCs are compact, stylish and professional," said Giorgio Johnson, founder and CEO of Nyxio. "Their versatility makes them the optimal choice for a multitude of users and the tablet's progressive features make them stand out from other brands on the market."
All three tablets in the OMEGA line-the Classic, Premier and Ultimate-feature Windows 7. The OMEGA Ultimate tablet also features a dual Win 7 and Android OS, and all tablets feature BlueStacks, which makes android apps compatible with the tablets. Integrated components also include Wi-Fi, Bluetooth, webcam and 3G. The touch-screen navigation enables users to move through applications and features easily. The optional keyboard case creates added protection and seamless transition when working, traveling or commuting. Currently, the OMEGA tablet line is available online at www.nyxio.com and pricing begins at $699.
Learn more about Smart TV's - Showcase Smart TV StockEmerging player - Nyxio Technologies Corporation (OTC: NYXO)
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/NYXO/
Request news or alerts on Nyxio Technologies Corporation (OTCBB: NYXO)
http://www.investorideas.com/Resources/Newsletter.asp
Nyxio Technologies (OTC: NYXO) was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as with the world's first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company with more than 15 knowledgeable employees. For more information visit: www.nyxio.com.
INVESTOR RELATIONS
Summit IR Services, Inc.
Phone: 1-855-436-6996 (NYXO)
info@nyxiotech.com
www.nyxio.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. NYXO is a paid advertising showcase company on Investorideas.com - three thousand per month from a third party
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
http://www.investorideas.com/About/Contact.asp
800-665-0411
Source - Investorideas.com
NYXIO TECH CORP (OTC: NYXO) is a showcase stock on Investorideas.com
Visit the company showcase profile page at www.investorideas.com/CO/NYXO
Get News and stock alerts for NYXO - Sign up here
Disclosure: NYXO is a showcase stock on Investorideas.com and the site is compensated three thousand per per month, third party, starting August 1, 2011
Wednesday, September 21, 2011
Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
SAN DIEGO � September 21, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today the introduction of HER2osome™, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25% of new breast cancer diagnosis.
The goal of HER2osome™ therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer. Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.
To support the pre-clinical and clinical advancement of HER2osome™, Aethlon has submitted a funding proposal entitled, "An Innovative Device Strategy to Eliminate HER2 Breast Cancer Progression" to the Breast Cancer Research Program (BCRP) offered through the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The BCRP was established in fiscal year 1992 (FY92) to support innovative research focused on eradicating breast cancer. Appropriations for the BCRP from FY92 through FY10 totaled over $2.5 billion. The FY11 appropriation is $150 million. Principal investigators underlying the Aethlon BCRP funding proposal are Dr. CS Chen, Chief, Division of Hematology and Oncology and Medical Director of the Loma Linda Cancer Center, and Dr. Douglas Taylor, Professor, Department of Obstetrics & Gynecology at University of Louisville School of Medicine.
The evolution of HER2osome™ therapy is based upon an adaptable dialysis-like affinity platform technology known as the Aethlon ADAPT™ system. Therapies evolved from the Aethlon ADAPT™ system target the selective clearance of harmful agents from the entire blood volume within clinically relevant time frames and without the loss of essential blood components. Thus, overcoming the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity agents in the outer-capillary space of plasma filtration membrane technology as a means to provide rapid real-time clearance of corresponding targets. In the case of HER2osome™, the immobilization of a HER2 antibody and an exosome targeted affinity agent provides a mechanism to clear both targets from the circulatory system of HER2+ breast cancer patients. Like all ADAPT™ derived therapies, HER2osome™ will operate dialysate free, will not require replacement fluids, and can be utilized on dialysis machines or CRRT systems already located in hospitals and clinics worldwide.
Aethlon has previously leveraged its ADAPT™ system through a proposal chosen for funding through a DOD contract award under DARPA-BAA-11-30 entitled "Dialysis-Like Therapeutics". The proposed program, which is pending completion of a contracting phase, would support the development of a therapeutic device that reduces the incidence of sepsis in wounded warfighters through the selective clearance of circulating septic precursors.
The genesis of the ADAPT™ system is the Hemopurifier®, a device that immobilizes a single lectin affinity agent to provide broad-spectrum capabilities against viral pathogens and immunosuppressive proteins. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both hepatitis-C (HCV) and HIV infected individuals without the administration of antiviral drugs. The device is currently the subject of a human clinical study to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the UnitedStates has been submitted to The Food and Drug Administration (FDA).
In vitro studies recently documented that the Hemopurifier® also captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. On August 24th, Aethlon expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration will study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Exosomes released by cancers have emerged to become an important therapeutic target in cancer care, as they are implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes may assist tumors in evading the response of the immune system.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO � September 21, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today the introduction of HER2osome™, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25% of new breast cancer diagnosis.
The goal of HER2osome™ therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer. Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.To support the pre-clinical and clinical advancement of HER2osome™, Aethlon has submitted a funding proposal entitled, "An Innovative Device Strategy to Eliminate HER2 Breast Cancer Progression" to the Breast Cancer Research Program (BCRP) offered through the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The BCRP was established in fiscal year 1992 (FY92) to support innovative research focused on eradicating breast cancer. Appropriations for the BCRP from FY92 through FY10 totaled over $2.5 billion. The FY11 appropriation is $150 million. Principal investigators underlying the Aethlon BCRP funding proposal are Dr. CS Chen, Chief, Division of Hematology and Oncology and Medical Director of the Loma Linda Cancer Center, and Dr. Douglas Taylor, Professor, Department of Obstetrics & Gynecology at University of Louisville School of Medicine.
The evolution of HER2osome™ therapy is based upon an adaptable dialysis-like affinity platform technology known as the Aethlon ADAPT™ system. Therapies evolved from the Aethlon ADAPT™ system target the selective clearance of harmful agents from the entire blood volume within clinically relevant time frames and without the loss of essential blood components. Thus, overcoming the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity agents in the outer-capillary space of plasma filtration membrane technology as a means to provide rapid real-time clearance of corresponding targets. In the case of HER2osome™, the immobilization of a HER2 antibody and an exosome targeted affinity agent provides a mechanism to clear both targets from the circulatory system of HER2+ breast cancer patients. Like all ADAPT™ derived therapies, HER2osome™ will operate dialysate free, will not require replacement fluids, and can be utilized on dialysis machines or CRRT systems already located in hospitals and clinics worldwide.
Aethlon has previously leveraged its ADAPT™ system through a proposal chosen for funding through a DOD contract award under DARPA-BAA-11-30 entitled "Dialysis-Like Therapeutics". The proposed program, which is pending completion of a contracting phase, would support the development of a therapeutic device that reduces the incidence of sepsis in wounded warfighters through the selective clearance of circulating septic precursors.
The genesis of the ADAPT™ system is the Hemopurifier®, a device that immobilizes a single lectin affinity agent to provide broad-spectrum capabilities against viral pathogens and immunosuppressive proteins. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both hepatitis-C (HCV) and HIV infected individuals without the administration of antiviral drugs. The device is currently the subject of a human clinical study to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the United
In vitro studies recently documented that the Hemopurifier® also captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. On August 24th, Aethlon expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration will study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Exosomes released by cancers have emerged to become an important therapeutic target in cancer care, as they are implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes may assist tumors in evading the response of the immune system.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Nyxio (OTC: NYXO ) Trading Alert : Consumer Electronic Stock Up 11.61% on News of New Product
POINT ROBERTS, September 21, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Consumer Electronic Company Nyxio Technologies Corporation
(OTC: NYXO). The stock is trading up 11.61% on news of a new product .
The Company announced its latest product line on the market—the OMEGA tablets. The fully functioning, sleek and compact Windows 7 operating system tablet PCs are compatible with all forms of media, gaming and social networking.
“The new Nyxio OMEGA PCs are compact, stylish and professional”
.“The new Nyxio OMEGA PCs are compact, stylish and professional,” said Giorgio Johnson, founder and CEO of Nyxio. “Their versatility makes them the optimal choice for a multitude of users and the tablet’s progressive features make them stand out from other brands on the market.”
All three tablets in the OMEGA line—the Classic, Premier and Ultimate—feature Windows 7. The OMEGA Ultimate tablet also features a dual Win 7 and Android OS, and all tablets feature BlueStacks, which makes android apps compatible with the tablets. Integrated components also include Wi-Fi, Bluetooth, webcam and 3G. The touch-screen navigation enables users to move through applications and features easily. The optional keyboard case creates added protection and seamless transition when working, traveling or commuting. Currently, the OMEGA tablet line is available online at www.nyxio.com and pricing begins at $699.
Learn more about Smart TV’s - Showcase Smart TV Stock
Emerging player - Nyxio Technologies Corporation (OTC: NYXO)
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/NYXO/
Request news or alerts on Nyxio Technologies Corporation (OTCBB: NYXO)
http://www.investorideas.com/Resources/Newsletter.asp
Nyxio Technologies (OTC: NYXO) was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as with the world's first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company with more than 15 knowledgeable employees. For more information visit: www.nyxio.com.
INVESTOR RELATIONS
Summit IR Services, Inc.
Phone: 1-855-436-6996 (NYXO)
info@nyxiotech.com
www.nyxio.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. NYXO is a paid advertising showcase company on Investorideas.com – three thousand per month from a third party
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
http://www.investorideas.com/About/Contact.asp
800-665-0411
Source – Investorideas.com
POINT ROBERTS, September 21, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Consumer Electronic Company Nyxio Technologies Corporation
(OTC: NYXO). The stock is trading up 11.61% on news of a new product .
The Company announced its latest product line on the market—the OMEGA tablets. The fully functioning, sleek and compact Windows 7 operating system tablet PCs are compatible with all forms of media, gaming and social networking.
“The new Nyxio OMEGA PCs are compact, stylish and professional”
.“The new Nyxio OMEGA PCs are compact, stylish and professional,” said Giorgio Johnson, founder and CEO of Nyxio. “Their versatility makes them the optimal choice for a multitude of users and the tablet’s progressive features make them stand out from other brands on the market.”
All three tablets in the OMEGA line—the Classic, Premier and Ultimate—feature Windows 7. The OMEGA Ultimate tablet also features a dual Win 7 and Android OS, and all tablets feature BlueStacks, which makes android apps compatible with the tablets. Integrated components also include Wi-Fi, Bluetooth, webcam and 3G. The touch-screen navigation enables users to move through applications and features easily. The optional keyboard case creates added protection and seamless transition when working, traveling or commuting. Currently, the OMEGA tablet line is available online at www.nyxio.com and pricing begins at $699.
Learn more about Smart TV’s - Showcase Smart TV Stock
Emerging player - Nyxio Technologies Corporation (OTC: NYXO)
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/NYXO/
Request news or alerts on Nyxio Technologies Corporation (OTCBB: NYXO)
http://www.investorideas.com/Resources/Newsletter.asp
Nyxio Technologies (OTC: NYXO) was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as with the world's first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company with more than 15 knowledgeable employees. For more information visit: www.nyxio.com.
INVESTOR RELATIONS
Summit IR Services, Inc.
Phone: 1-855-436-6996 (NYXO)
info@nyxiotech.com
www.nyxio.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. NYXO is a paid advertising showcase company on Investorideas.com – three thousand per month from a third party
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
http://www.investorideas.com/About/Contact.asp
800-665-0411
Source – Investorideas.com
Subscribe to:
Posts (Atom)